<DOC>
	<DOC>NCT01646814</DOC>
	<brief_summary>This trial is a Phase 2, randomized, controlled study to compare the degree of mucosal injury after the oral administration of an investigational product, PL2200, and a marketed 325 mg immediate-release aspirin product. Each group will be treated with either an immediate-release aspirin tablet or PL2200 capsule at 325 mg per day for 6 weeks, and evaluated via an endoscope for any gastrointestinal injury that may have been caused by study medication.</brief_summary>
	<brief_title>Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Healthy volunteers, ≥50 and ≤75 years of age. No endoscopically observed baseline gastrointestinal lesions. Baseline gastrointestinal lesions or abnormal screening/baseline laboratory parameters deemed clinically significant by the Investigator. Significant history of substance abuse or uncontrolled acute or chronic medical illness. Active H. pylori infection. Current use of lowdose aspirin for cardioprevention, or other ulcerogenic medications, gastroprotective, or antiplatelet agents. Hypersensitivity to aspirin or other NSAIDs.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>comparison of incidence of</keyword>
	<keyword>treatment groups.</keyword>
</DOC>